Acuitas Investments LLC Boosts Position in AngioDynamics, Inc. (NASDAQ:ANGO)

Acuitas Investments LLC lifted its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 8.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 403,280 shares of the medical instruments supplier’s stock after acquiring an additional 31,480 shares during the period. AngioDynamics accounts for approximately 1.6% of Acuitas Investments LLC’s portfolio, making the stock its 19th biggest position. Acuitas Investments LLC owned about 1.01% of AngioDynamics worth $3,162,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Swiss National Bank raised its holdings in shares of AngioDynamics by 2.3% during the 3rd quarter. Swiss National Bank now owns 86,300 shares of the medical instruments supplier’s stock worth $631,000 after acquiring an additional 1,900 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in AngioDynamics by 37.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,105 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 2,491 shares during the period. Moody National Bank Trust Division raised its holdings in AngioDynamics by 22.8% in the 4th quarter. Moody National Bank Trust Division now owns 15,439 shares of the medical instruments supplier’s stock valued at $121,000 after buying an additional 2,866 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in AngioDynamics by 11.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 34,010 shares of the medical instruments supplier’s stock valued at $249,000 after buying an additional 3,442 shares during the period. Finally, Gladius Capital Management LP purchased a new stake in AngioDynamics in the 3rd quarter valued at about $30,000. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Insiders Place Their Bets

In other AngioDynamics news, CEO James C. Clemmer purchased 10,000 shares of the business’s stock in a transaction on Monday, April 8th. The shares were bought at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the completion of the purchase, the chief executive officer now directly owns 539,066 shares of the company’s stock, valued at $3,611,742.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Oppenheimer upgraded shares of AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price objective on the stock in a report on Friday, April 5th. HC Wainwright reduced their price objective on shares of AngioDynamics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, January 8th. Finally, Raymond James cut their price target on shares of AngioDynamics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 9th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, AngioDynamics currently has an average rating of “Moderate Buy” and an average target price of $14.25.

AngioDynamics Stock Down 2.7 %

NASDAQ:ANGO traded down $0.16 on Wednesday, reaching $5.87. 586,457 shares of the company’s stock were exchanged, compared to its average volume of 577,346. The firm has a market capitalization of $235.15 million, a price-to-earnings ratio of -1.21 and a beta of 0.66. The business has a fifty day moving average of $5.93 and a 200-day moving average of $6.42. AngioDynamics, Inc. has a 52-week low of $5.26 and a 52-week high of $11.38.

AngioDynamics Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.